Current trends in the use of heparins in thromboprophylaxis

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 2 SUPPL. 1, 1999, Pages 29-35

  Green, David ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Anticoagulants; Heparin; Low molecular weight heparin; Thromboembolism; Thromboprophylaxis; Thrombosis; Venous disease

Indexed keywords

ACETYLSALICYLIC ACID; ARDEPARIN; DALTEPARIN; DANAPAROID; ENOXACIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN; WARFARIN;

ANTICOAGULATION; BLEEDING; BREAST CANCER; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONFERENCE PAPER; DEEP VEIN THROMBOSIS; DRUG EFFICACY; HEPARINIZATION; HUMAN; LEG COMPRESSION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; STROKE; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; TOTAL HIP PROSTHESIS;

EID: 0032948429     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. Halkin H, Goldberg J, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982;96:561-565
2. Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. N Engl J Med 1988; 318:1162-1173
3. Clagett GP, Anderson FA Jr, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995;108 (Suppl):312S-334S
4. Wijdicks EFM, Scott JP. Pulmonary embolism associated with acute stroke. Mayo Clin Proc 1997;72:297-300
5. Prins MH, Gelsema R, Sing AK, van Heerde LR, den Ottolander GJH. Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. Haemostasis 1989;19:245-250
6. Turpie AGG, Gent M, Cote R, et al. A low-molecular-weight heparinoid compared with unfractionated heparin in the prevention of deep-vein thrombosis in patients with acute ischemic stroke. Ann Intern Med 1992;117:353-357
7. Kay R, Wong KS, Yu YL, et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995;333:1588-1593
8. Green D, Akuhota V, Eiken M, et al. Prevention of thromboembolism in stroke rehabilitation patients. Topics in Stroke Rehabilitation 1998;5:68-74
9. Rossi EC, Green D, Rosen J. Sequential changes in factor VIII and platelets preceding deep vein thrombosis in patients with spinal cord injury. Br J Haematol 1980;45:143-151
10. Merli GJ, Crabbe S, Paluzzi RG, et al. Etiology, incidence, and prevention of deep-vein thrombosis in acute spinal cord injury. Arch Phys Med Rehab 1993;74:1199-1205
11. Green D. Prophylaxis of thromboembolism in spinal cord-injured patients. Chest 1994;102(Suppl):649S-651S
12. Green D, Lee MY, Ito VY, et al. Fixed versus adjusted dose heparin in the prophylaxis of thromboembolism in spinal cord injury. JAMA 1988;260:1255-1258
13. Green D, Lee MY, Lim AC, et al. Low-molecular-weight heparin in the prevention of thromboembolism after spinal cord injury. Ann Intern Med 1990;113:571-574
14. Green D, Chen D, Chmiel JS, et al. Prevention of thromboembolism in spinal cord injury: Role of low-molecular-weight heparin. Arch Phys Med Rehab 1994;75:290-292
15. Harris S, Chen D, Green D. Enoxaparin for thromboembolism prophylaxis in spinal injury: A preliminary report on the experience with 105 patients. Am J Phys Med Rehab 1996;75:326-327
16. Nurmohamed MT, van Riel AM, Henkens CMA, et al. Low-molecular-weight heparin and compression stockings in the prevention of venous thromboembolism in neurosurgery. Thromb Haemostas 1996;75:233-238
17. Agnelli G, Piovella F, Buoncristiani P, et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998;339:80-85
18. Geerts WH, Jay RM, Code KI, et al. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996;335:701-707
19. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994;271:1780-1785
20. Heit JA, Berkowitz SD, Bona R, et al. Efficacy and safety of low-molecular-weight heparin (Ardeparin sodium) compared to warfarin for the prevention of venous thromboembolism after total knee replacement surgery: A double-blind, dose-ranging study. Thromb Haemostas 1997;77:32-38
21. Hull R, Raskob G, Pineo G, et al. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 1993;329:1370-1376
22. Hamulyak K, Lensing AWA, van der Meer J, et al. Subcutaneous low-molecular-weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Thromb Haemostas 1994;74:1428-1431
23. Spiro TE, Fitzgerald RH, Trowbridge AA, et al. Enoxaparin a low-molecular-weight heparin and warfarin for the prevention of venous thromboembolic disease after elective knee replacement surgery. Blood 1994;84:246(Abst)
24. Leclerc JR, Geerts WH, Desjardins L, et al. Prevention of venous thromboembolism after knee arthroplasty. Ann Intern Med 1996;124:619-626
25. Planes A, Vochelle N, Darmon J-Y, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996;348:224-228
26. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696-700
27. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery - results of a double-blind, prospective, randomised placebo-controlled study with dalteparin (Fragmin). Thromb Haemostas 1997;77:26-31
28. Leclerc JR, Gent M, Hirsh J, Geerts W, Ginsberg JS, and members of the Canadian Cohort Group. The incidence of symptomatic venous thromboembolism during and after prophylaxis with enoxaparin: A multi-institutional cohort study of patients who underwent hip or knee arthroplasty. Arch Intern Med 1998;158:873 878
29. Ricotta S, Iorio A, Parise P, Nenci GG, Agnelli G. Post discharge clinically overt venous thromboembolism in orthopaedic surgery patients with negative venography - an overview analysis. Thromb Haemostas 1996;76:887-892
30. Colwell CW, Hinson J, McCutchen JW, Paulson R, Collis DK. Enoxaparin versus warfarin: Hospital management for prevention of venous thromboembolic disease following total hip arthroplasty. Presented at the 64th Annual Meeting of the American Association of Orthopedic Surgeons, San Francisco, February 1997, paper #353
31. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de Paris, London: New Sydenham Society; 1865:282-332
32. Minna JD, Bunn PA Jr. Paraneoplastic syndromes. In: DeVita VT Jr., Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 3rd ed. Philadelphia: Lippincott, 1989: 1920-1940
33. Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in patients with cancer. J Med 1975;6:61-64
34. Sproule EE. Carcinoma and venous thrombosis: The frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938;34: 566-585
35. Pineo GF, Brain ML, Galkes AS, et al. Tumors, mucus production and hypercoagulability. Ann NY Acad Sci 1974;230:262-270
36. Schreiber DP, Kapp DS. Axillary-subclavian vein thrombosis following combination chemotherapy and radiation, Int J Radiation Oncol Biol Physics 1986;12:391-395
37. Wilson CB, Lambert HE, Scott RD. Subclavian and axillary vein thrombosis following radiotherapy for carcinoma of the breast. Clin Radiol 1987;38:95-96
38. Weiss B, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Rep 1981;65:677 679
39. Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five drug chemotherapy regimen. Cancer 1984;54:1264-1268
40. Levine MN, Gent M, Hirsh J, et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988;318:404-408
41. Levine M, Hirsh J, Gent M, et al. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994;343:886-889
42. Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low-molecular-weight heparin fragment (Fragmin). Thromb Haemostas 1989;62:1046-1049
43. Enoxacan Study Group. Efficacy and safely of enoxaparin vs unfractionated heparin for prevention of deep-vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment. Br J Surg 1997;84: 1099 1103
44. Walsh-McMonagle D, Green D. Low-molecular-weight heparin in the management of Trousseau's syndrome. Cancer 1997;80: 649-655
45. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemostas 1998;80:10-23